Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318617 · ClinicalTrials.gov registry record
Effect Of GW501516X On How The Heart Obtains And Uses Energy
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 30
- Enrollment target
NCT00318617 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 30 participants.
The verdict
NCT00318617 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.
Interventions
- DRUG GW510516X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318617
The ClinicalTrials.gov registry entry for NCT00318617 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW510516X is the first listed.
NCT00318617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318617 about?
NCT00318617 is a clinical study titled "Effect Of GW501516X On How The Heart Obtains And Uses Energy". The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, ...
What is the current status of trial NCT00318617?
This trial is currently terminated. The enrollment target is 30 participants. The study started on 2005-12.
What interventions are being tested in trial NCT00318617?
The interventions under investigation include: GW510516X (DRUG).
Who is sponsoring clinical trial NCT00318617?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.